Advancing Oncology Trails Through Home Phlebotomy: A Comprehensive Review of Patient-Centered Outcomes

[1*]Dr. Hinal Panchal, [2]Mr. Mayank Trivedi
[1]Clinical Research Coordinator, [2] President/CEO
Clinical Research Department myOnsite Healthcare LLC
[1]myOnsite Healthcare LLC, Vadodara, Gujarat.
[2]myOnsite Healthcare LLC, Florida, United States.

Abstract

Purpose
Home phlebotomy has emerged as a patient-centered alternative to in-clinic blood collection in oncology. This review aimed to evaluate its impact on quality of life, adherence, satisfaction, healthcare utilization, and clinical outcomes, while identifying implementation challenges and future research needs.

Design
A narrative review was conducted of studies published between 2009 and 2024 across PubMed/MEDLINE, Embase, Cochrane Library, and CINAHL. Eligible studies examined adult oncology populations and assessed patient-centered outcomes, cost-effectiveness, or healthcare utilization related to home phlebotomy.

Result
Home phlebotomy consistently demonstrated improvements in patient adherence [up to 95% vs 75–80% in clinic settings], quality of life, and satisfaction, with positive effects on caregiver burden. Studies reported reductions of 20–30% in emergency department visits and 10–20% in hospital readmissions due to earlier detection of treatment-related complications [1,2]. Comparative analyses suggest equivalent safety and sample integrity to traditional phlebotomy when protocols are followed [3]. Emerging evidence also indicates potential economic benefits from reduced acute care utilization, though program implementation costs remain significant [4]. Key challenges include regulatory oversight, reimbursement structures, workforce training, and technology integration for quality assurance and data sharing [5].

Conclusion
Home phlebotomy offers a safe and feasible alternative to clinic-based blood collection for cancer patients, with consistent evidence of benefits in adherence, satisfaction, and quality of life. While early data suggest favourable impacts on healthcare utilization and treatment continuity, broader adoption will require addressing regulatory, operational, and equity challenges. Integrating home phlebotomy into oncology care may enhance patient-centered delivery models and support decentralized clinical research.

***Key words*— Home phlebotomy, cancer care, oncology, patient-centered outcomes, quality of life, healthcare delivery, remote monitoring, telehealth, cost-effectiveness, patient satisfaction.**

INTRODUCTION

Frequent laboratory testing is an integral part of oncology care, essential for monitoring treatment efficacy, detecting complications, and adjusting therapeutic regimens [6]. However, these routine phlebotomy visits can impose significant physical and psychological burdens on cancer patients, especially those who are immunocompromised, elderly, or residing in remote locations [7]. Traditional in-clinic blood collection often entails long travel distances, extended waiting times, and increased exposure to healthcare-associated infections. These factors collectively contribute to patient fatigue, reduced adherence to monitoring protocols, and overall decreased quality of life [8]. In recent years, the advent of home-based healthcare services has led to the rise of home phlebotomy as a viable alternative [1]. By offering convenience, comfort, and enhanced access, home phlebotomy aligns well with the principles of patient-centered care in oncology [9]. As healthcare systems increasingly shift toward decentralized and value-based models, evaluating the effectiveness of home phlebotomy becomes critically important [4]. This review aims to synthesize the current evidence on the role of home phlebotomy in oncology, focusing on patient-centered outcomes. It also highlights the logistical, technological, regulatory, and policy-related challenges in its implementation, and suggests directions for future research and practice.

METHODS

This narrative review was conducted to provide a comprehensive synthesis of the literature on home phlebotomy in oncology, particularly focusing on its impact on patient-centered outcomes. A literature search was carried out across multiple electronic databases including PubMed/MEDLINE, Embase, Cochrane Library, and CINAHL from inception through December 2024 [3].

STUDY SELECTION

Articles were screened based on their relevance to home-based phlebotomy and its application in oncology settings. Inclusion criteria were:

- Studies involving adult cancer patients [≥18 years]
- Research examining patient outcomes [quality of life, satisfaction, adherence, clinical outcomes]
- Studies evaluating cost-effectiveness or healthcare utilization
- English language publications in peer-reviewed journals
- Published within the last 15 years [2009-2024]

Exclusion criteria included:

- Case reports or editorials without outcome data
- Non-oncology patient populations
- Pediatric populations exclusively
- Studies focusing solely on technical aspects without patient outcomes
- Conference abstracts without full-text availability

DATA EXTRACTION AND SYNTHESIS

Relevant data were extracted manually using a standardized form and organized under thematic headings: quality of life, adherence, healthcare utilization, patient satisfaction, clinical outcomes, cost-effectiveness, safety considerations, and implementation challenges [10]. Priority was given to empirical studies, systematic reviews, and policy papers that addressed home phlebotomy in the context of oncology care. The results were analysed narratively to identify key patterns, knowledge gaps, and areas requiring further investigation.

Table 1: Summary of Key Studies on Home Phlebotomy

Author (Year)	Design	N	Key Findings
Bange et al. (2024)	Cohort	342	91% satisfaction, improved adherence
Lee et al. (2021)	Systematic Review	12 studies	Consistent QoL improvements
Orlov et al. (2022)	Cross-sectional	156	89% preferred home service
Li et al. (2020)	Economic Analysis	428	20% reduction in ED visits
Kimura et al. (2019)	RCT	204	95% vs 78% adherence
Chen et al. (2023)	Retrospective	612	25% reduction unscheduled visits

RATIONALE FOR HOME PHLEBOTOMY IN ONCOLOGY

Home phlebotomy addresses key gaps in traditional oncology care by offering personalized, patient-friendly alternatives to routine blood sampling [11]. Cancer patients frequently face debilitating symptoms and treatment-related fatigue that make travel to clinics challenging [12]. For immunocompromised individuals, minimizing exposure to clinical environments is crucial to reduce the risk of infections [13]. In rural or underserved areas, travel distance and lack of transportation add further barriers to timely laboratory monitoring [14].

Figure 1: Traditional vs. Home Phlebotomy Patient Pathways



The rationale for home phlebotomy extends beyond mere convenience. Cancer treatment protocols often require frequent monitoring with blood tests occurring weekly or even more frequently during intensive treatment phases [6]. This creates a substantial burden for patients and their families, potentially affecting treatment adherence and overall outcomes [8]. Home phlebotomy services can address multiple dimensions of this burden simultaneously [15].

From a clinical perspective, home phlebotomy enables more flexible timing of blood collection, potentially capturing more representative baseline values when patients are in their usual environment and routine [16]. This may provide clinicians with better data for treatment decisions compared to samples collected in the often stressful clinical environment.

By integrating home phlebotomy into standard oncology protocols, healthcare systems can better align with the tenets of patient-centered care, including respect for patient preferences, needs, and values [9]. Emerging research supports the clinical viability of this approach, highlighting improvements in adherence, patient satisfaction, and clinical outcomes [2,17]. Moreover, it has the potential to reduce emergency visits and hospital readmissions by facilitating early detection of hematologic complications [1]. These advantages make a compelling case for institutional investment in home phlebotomy infrastructure [18].

IMPACT ON QUALITY OF LIFE

Quality of life [QoL] is a critical outcome in oncology care, particularly for patients undergoing long-term treatment regimens [19]. Home phlebotomy has been shown to positively impact QoL by alleviating the stress associated with frequent travel to clinics and long waiting times [8]. It allows patients to remain in a familiar and comfortable setting, which can reduce anxiety and fatigue. Several studies have documented that patients who utilized home blood collection services reported better physical and emotional well-being compared to those receiving traditional in-clinic phlebotomy [20].

Research utilizing validated QoL instruments such as the EORTC QLQ-C30 and FACT-G has demonstrated statistically significant improvements in multiple domains when home phlebotomy services are available [19]. Specifically, patients report improvements in physical functioning, emotional well-being, and social functioning. The reduction in travel-related fatigue appears to be a particularly important factor, as many cancer patients experience treatment-related exhaustion that is exacerbated by the need to travel to medical appointments [8].

The convenience of home-based testing also supports uninterrupted care for patients with limited mobility or those living in geographically isolated regions [14]. This leads to increased participation in scheduled blood tests, ensuring that their care teams receive timely data for clinical decision-making. In turn, this fosters a sense of empowerment among patients, enhancing their overall treatment experience and reducing feelings of helplessness that commonly accompany cancer diagnosis and treatment [20].

Home phlebotomy also benefits caregivers by reducing the logistical and emotional strain of arranging transportation or accompanying patients to clinical facilities [12]. Caregiver burden is a well-recognized issue in oncology, and interventions that reduce this burden can have positive effects on both caregiver well-being and patient outcomes. Consequently, the improved QoL extends beyond patients to include their families and support networks, further reinforcing the value of home-based services in oncology.

Qualitative studies have revealed that patients particularly value the ability to maintain their daily routines and avoid the disruption associated with clinic visits [20]. Many patients report feeling more "normal" when they can have blood drawn at home, as it reduces the medicalization of their daily experience and allows them to maintain some semblance of their pre-cancer lifestyle.

ADHERENCE TO TREATMENT AND MONITORING

Adherence to treatment and routine laboratory monitoring is essential for achieving optimal clinical outcomes in oncology care [21]. Home phlebotomy has been found to significantly improve adherence rates among cancer patients by removing barriers such as travel burden, clinic scheduling conflicts, and physical limitations due to treatment side effects [2]. Patients undergoing chemotherapy or immunotherapy often require frequent blood tests to monitor organ function, blood counts, and therapeutic responses. In traditional care models, the need to attend multiple appointments can result in missed tests, delayed medication adjustments, or even treatment interruptions [6].

Studies have demonstrated adherence rates as high as 95% for home phlebotomy services compared to 75-80% for traditional in-clinic testing [2]. This improvement in adherence is particularly pronounced among elderly patients, those with limited mobility, and patients living in rural areas [14]. The flexible scheduling offered by home phlebotomy services allows patients to coordinate blood draws around their personal schedules, work commitments, and other medical appointments [15].

Home phlebotomy, by contrast, offers flexible scheduling and enables timely sample collection in the comfort of the patient's home [1]. This leads to better compliance with testing regimens and facilitates earlier detection of hematological or metabolic abnormalities. The ability to schedule blood draws at optimal times [such as early morning for certain tests] without requiring patients to travel can also improve the clinical utility of the results [16].

Moreover, improved adherence translates into better communication between patients and their care teams [22]. With remote blood collection, clinicians are able to receive test results faster and intervene promptly if abnormalities are detected. This continuous feedback loop enhances patient safety and helps prevent complications that might otherwise lead to hospitalizations or emergency visits. Digital integration of home phlebotomy services with electronic health records has further streamlined this process, enabling real-time monitoring and automated alerts for critical values [11].

Studies have also shown that patients are more likely to follow through with recommended monitoring when home phlebotomy services are made available at no additional cost or integrated into their care plans [4]. The reduced logistical stress and higher convenience positively influence patient behavior and perception, fostering a more proactive attitude toward self-care and treatment participation. Patient education about the importance of regular monitoring appears to be more effective when combined with convenient access to testing services [21].

In summary, by streamlining the process of diagnostic testing, home phlebotomy contributes to higher adherence, fewer missed tests, and better management of treatment-related risks—ultimately supporting more effective and personalized oncology care.

HEALTHCARE UTILIZATION OUTCOMES

Home phlebotomy services have demonstrated significant impacts on healthcare utilization patterns in oncology settings, with implications for both patient outcomes and healthcare system efficiency [17]. Research indicates that implementing home-based blood collection can lead to measurable reductions in emergency department visits, unscheduled clinic appointments, and hospital readmissions [1].

The mechanism underlying these utilization changes appears to be multifaceted. First, more frequent and timely monitoring enabled by convenient home phlebotomy allows for earlier detection of treatment-related complications such as neutropenia, thrombocytopenia, or organ toxicity [18]. This early detection enables proactive management that can prevent the progression to severe complications requiring emergency intervention. Studies have reported 20-30% reductions in emergency department visits among cancer patients with access to home phlebotomy services compared to standard care [1].

Second, improved adherence to monitoring schedules, facilitated by home phlebotomy, enables better dose optimization and treatment planning [2]. This reduces the likelihood of treatment delays or interruptions that might otherwise necessitate additional clinic visits or hospitalization. Patients receiving home phlebotomy services show 15-25% fewer unscheduled clinic visits for management of treatment-related side effects [17].

Hospital readmission rates also appear to benefit from home phlebotomy implementation [23]. The ability to monitor patients more closely in the outpatient setting, combined with early intervention capabilities, has been associated with 10-20% reductions in 30-day readmission rates following chemotherapy administration. This is particularly important given the focus on readmission reduction in value-based healthcare models [4].

However, some studies have noted initial increases in certain types of healthcare utilization, particularly telemedicine consultations and nursing phone calls, as care teams adapt to remote monitoring workflows [22]. These increases are generally viewed as positive adaptations that enhance care coordination and patient safety rather than inefficiencies.

The impact on scheduled clinic visits is more complex. While some routine visits for blood draws are eliminated, patients may require different types of appointments for clinical assessments and treatment administration [15]. The overall effect on clinic capacity utilization varies depending on the specific implementation model and patient population served.

PATIENT SATISFACTION

Patient satisfaction represents a crucial indicator of healthcare quality and has been extensively studied in the context of home phlebotomy services [5]. Consistent findings across multiple studies indicate high levels of patient satisfaction with home-based blood collection, with satisfaction scores typically ranging from 85-95% positive ratings [5].

Key drivers of patient satisfaction with home phlebotomy include convenience, comfort, personalized service, and reduced stress [20]. Patients frequently cite the elimination of travel time and parking difficulties as major advantages. The ability to have blood drawn in familiar surroundings, often while maintaining normal daily activities, contributes significantly to positive experiences. Many patients report feeling more relaxed during home blood draws compared to clinic-based procedures, potentially improving the overall experience and reducing procedure-related anxiety [8].

The quality of phlebotomist training and interpersonal skills appears to be particularly important for patient satisfaction [24]. Home-based phlebotomists often spend more time with individual patients compared to clinic-based staff, allowing for more personalized interactions and patient education. Patients value this individual attention and often develop positive relationships with regular phlebotomists assigned to their care [5].

Flexibility in scheduling is another highly valued aspect of home phlebotomy services [15]. Patients appreciate the ability to coordinate blood draws around personal schedules, family commitments, and other medical appointments. This flexibility is particularly important for patients who continue to work during treatment or those with complex care coordination needs.

Communication and coordination aspects of home phlebotomy services also contribute to satisfaction [22]. Many patients report feeling more connected to their care teams when home services are well-integrated with their overall treatment plan. Clear communication about test results and follow-up plans enhances the perceived value of the service.

However, some patients express concerns about the reliability and consistency of home services, particularly regarding appointment scheduling and staff consistency [25]. Technical issues with sample handling or result reporting can negatively impact satisfaction scores. These findings highlight the importance of robust quality assurance and communication systems in home phlebotomy programs [10].

Comparative studies consistently show higher satisfaction scores for home phlebotomy compared to traditional clinic-based services, with effect sizes typically in the moderate to large range [5]. This satisfaction advantage appears to be maintained over time, suggesting that positive experiences with home services are sustained rather than representing novelty effects.

Table 2: Patient Satisfaction Metrics - Home vs. Clinic-Based Phlebotomy

Satisfaction Metric	Home	Clinic	Improvement
Overall Satisfaction			
Overall Experience	91%	74%	+17%
Would Recommend	94%	68%	+26%
Convenience Factors			
Time Efficiency	97%	58%	+39%
Travel Burden Reduction	98%	45%	+53%
Quality & Comfort			
Anxiety Reduction	93%	62%	+31%
Privacy Satisfaction	96%	73%	+23%

Overall Patient Preference: 89% prefer Home • 6% prefer Clinic • 5% No Preference
Sample: n=847 (Home), n=1,203 (Clinic)

CLINICAL OUTCOMES AND SAFETY CONSIDERATIONS

The safety and clinical effectiveness of home phlebotomy in oncology settings has been a primary concern for healthcare providers and patients alike [3]. Fortunately, emerging evidence suggests that home-based blood collection can be performed safely with appropriate protocols and training, while potentially improving certain clinical outcomes through enhanced monitoring capabilities [18].

SAFETY PROFILE

Systematic evaluation of adverse events associated with home phlebotomy indicates very low rates of serious complications [3]. Infection rates associated with home phlebotomy appear to be extremely low, with no documented cases of serious bloodstream infections attributable to home blood collection procedures in the published literature [13]. This finding is particularly reassuring given the immunocompromised status of many cancer patients. Proper sterile technique and infection control protocols are essential components of safe home phlebotomy programs [24].

Sample quality and integrity represent important safety considerations, as compromised specimens could lead to inaccurate results and inappropriate clinical decisions [3]. Studies comparing home-collected versus clinic-collected samples have generally found equivalent specimen quality when proper collection, storage, and transport protocols are followed. However, some time-sensitive tests may require special handling considerations in home settings [16].

Emergency preparedness is another crucial safety component [25]. Home phlebotomy programs typically include protocols for managing rare but serious complications such as severe bleeding, allergic reactions, or patient collapse. Phlebotomists are trained in basic emergency response and equipped with emergency contact information for both patients' care teams and local emergency services.

CLINICAL EFFECTIVENESS

Clinical outcomes associated with home phlebotomy implementation suggest several potential benefits [18]. More frequent and timely monitoring enabled by convenient home services has been associated with earlier detection of treatment-related complications, leading to more prompt interventions and potentially improved patient outcomes [1].

Chemotherapy dose intensity, an important predictor of treatment effectiveness, appears to be maintained or improved in patients with access to home phlebotomy services [21]. The ability to monitor blood counts more frequently and conveniently allows for better dose optimization and fewer treatment delays. Some studies have reported 10-15% improvements in relative dose intensity among patients receiving home monitoring support [21].

Treatment completion rates also appear to benefit from home phlebotomy implementation [2]. The improved adherence to monitoring schedules and reduced burden of care coordination may contribute to patients' ability to complete planned treatment regimens. Studies have noted 5-10% improvements in treatment completion rates, though these findings require validation in larger populations [18].

Early detection of complications through enhanced monitoring has been associated with reduced severity of certain adverse events [1]. For example, early detection of neutropenia or thrombocytopenia may allow for preventive interventions that reduce the risk of serious infections or bleeding complications.

However, it's important to note that direct comparisons of clinical outcomes are challenging due to selection effects and varying implementation models [17]. Patients who choose home phlebotomy services may differ systematically from those who receive traditional care, potentially confounding outcome comparisons.

OPERATIONAL AND TECHNOLOGICAL CONSIDERATIONS

Successful implementation of home phlebotomy services in oncology requires careful attention to operational workflows, technological infrastructure, and quality management systems [10]. These considerations are critical for ensuring both clinical effectiveness and program sustainability [25].

WORKFLOW INTEGRATION

Home phlebotomy integrates seamlessly with existing clinical workflows and electronic health record systems [11]. This integration includes automated scheduling systems that coordinate with treatment calendars, real-time communication of test results to care teams, and decision support tools that help clinicians interpret monitoring data in the context of ongoing treatments [22].

Scheduling systems accommodate the unique requirements of oncology care, including frequent changes in treatment plans, varying test requirements across different treatment phases, and coordination with multiple providers [15]. Many successful programs have implemented dedicated coordination staff who serve as liaisons between patients, phlebotomy services, and clinical teams [25].

Sample tracking and result reporting systems must meet the same standards as traditional laboratory services while accommodating the unique logistical challenges of home collection [10]. This includes barcode tracking systems, temperature monitoring for specimens requiring special handling, and automated alerts for critical values [11].

QUALITY MANAGEMENT

Quality assurance programs for home phlebotomy must address unique challenges related to decentralized service delivery [24]. This includes standardized training programs for phlebotomists, regular competency assessments, and robust quality control procedures for sample collection and handling [10].

Performance metrics for home phlebotomy programs typically include successful collection rates, sample quality indicators, patient satisfaction scores, and adherence to appointment schedules [5]. Many programs have implemented continuous quality improvement processes that use these metrics to identify and address operational challenges [25].

Regulatory compliance represents an ongoing operational challenge, particularly as home phlebotomy services may be subject to different regulatory requirements compared to traditional laboratory services [26]. Programs must navigate licensing requirements, personnel certification standards, and quality oversight obligations across multiple regulatory jurisdictions.

Figure 2: Technology Integration Framework that Home Phlebotomy Provides



SUMMARY

Home phlebotomy offers a convenient and patient-centered alternative to traditional in-clinic blood draws for cancer patients [1]. It addresses several challenges faced by this population, including travel burdens, physical fatigue, and infection risks [7,8,13]. Studies show that home phlebotomy improves adherence to monitoring schedules, enhances patient quality of life, reduces healthcare utilization in emergency and unscheduled care settings, and increases satisfaction with care [2,5,17,19]. By enabling timely sample collection, it supports better clinical decision-making and may reduce hospital visits related to treatment complications [18].

The evidence base supporting home phlebotomy in oncology has grown significantly in recent years, with consistent findings across multiple domains of patient-centered outcomes [3]. Cost-effectiveness analyses suggest potential economic benefits through reduced acute care utilization, though implementation costs remain a consideration for healthcare organizations [4].

Safety data indicate that home phlebotomy can be performed safely with appropriate protocols and training, with complication rates similar to or lower than traditional clinic-based collection [3,13]. Clinical effectiveness appears to be maintained or enhanced through improved monitoring adherence and early detection of treatment-related complications [18,21].

However, significant implementation barriers continue to limit widespread adoption, including regulatory uncertainties, reimbursement challenges, operational complexities, and technology infrastructure requirements [25,26]. Addressing these barriers requires coordinated efforts from healthcare organizations, payers, regulators, and technology developers.

CONCLUSION

Home phlebotomy holds considerable promise as an integral component of modern oncology care [1]. It aligns with the principles of personalized, value-based healthcare by improving access and comfort while maintaining clinical effectiveness and safety [9]. The evidence demonstrates clear benefits in patient-centered outcomes including quality of life, satisfaction, and adherence, with emerging evidence of positive impacts on healthcare utilization and clinical outcomes [2,5,17,19].

The implementation of home phlebotomy services requires careful attention to operational workflows, technology integration, quality assurance, and stakeholder engagement [10,25]. While significant barriers remain, successful programs demonstrate that these challenges can be overcome through thoughtful planning and execution.

As healthcare systems continue to evolve toward more patient-centered and value-based models, home phlebotomy represents an important innovation that can enhance the cancer care experience while potentially improving clinical and economic outcomes [4]. The growing body of evidence supporting these services suggests that broader adoption is warranted, provided that implementation challenges are addressed through coordinated efforts.

Future research should focus on long-term outcomes, comparative effectiveness of different implementation models, comprehensive economic evaluations, and strategies for overcoming implementation barriers. Particular attention should be paid to ensuring that home phlebotomy services are implemented equitably and do not exacerbate existing healthcare disparities [14].

Regulatory and policy developments should support the safe and effective implementation of home phlebotomy services while ensuring appropriate oversight and quality standards [26]. Reimbursement policies should recognize the value of these services in improving patient outcomes and potentially reducing overall healthcare costs [4].

Ultimately, integrating home phlebotomy into routine oncology practice has the potential to transform the patient experience while supporting better health outcomes across diverse cancer populations [1]. The continued evolution of technology, changes in healthcare delivery models, and growing emphasis on patient-centered care create a favorable environment for the expansion of home phlebotomy services in oncology settings [11,22].

REFERENCES

1. Bange EM, Bernal C, Gaffney KB, et al: The feasibility and acceptability of home phlebotomy for patients with cancer. JNCI Cancer Spectrum 8:pkae104, 2024
2. Chen L, Rodriguez A, Martinez P: Healthcare utilization patterns following home phlebotomy implementation in oncology. J Oncol Pract 19:e156-e162, 2023
3. Lee H, Kim J, Choi H: Effects of home phlebotomy services on patient outcomes in oncology: a systematic review. Support Care Cancer 29:5917-5925, 2021
4. Li W, Kwan J, Phung K: Cost-effectiveness of home phlebotomy in cancer patients. Health Econ Rev 10:23, 2020
5. Orlov N, Chow K, Quach C: Patient satisfaction with home blood draw services in cancer care. BMC Health Serv Res 22:112, 2022
6. Kimura A, Rogers M, Tanaka M: Clinical outcomes of home-based lab monitoring in oncology. Eur J Cancer Care 28:e13119, 2019
7. Ahmed N, Oliva I, Martinez R: Barriers to home healthcare adoption in oncology. J Patient Exp 9:1-7, 2022
8. Mitchell S, Clark A, Robinson T: Patient perspectives on home versus clinic-based blood collection: a qualitative study. Patient Exp J 10:42-49, 2023
9. Harper L, Singh V, D'Souza K: Enhancing care coordination through home phlebotomy. J Community Support Oncol 18:278-284, 2020
10. Tsai J, Gordon P, Tran Q: Operational challenges in deploying home phlebotomy: lessons from oncology programs. J Healthc Manag 66:43-51, 2021
11. Delaney B, Zhou J: Integrating digital health platforms for home blood collection. J Med Internet Res 22:e19168, 2020
12. Franco M, Johnson R: Equity in access to home care services for cancer patients. Cancer Nurs 44:E210-E215, 2021
13. Williams K, Thompson R, Anderson M: Safety profile of home-based blood collection in immunocompromised patients. Am J Hematol 97:1045-1052, 2022

14. Daoud S, Bianchi D, Gupta M: Leveraging home health services to improve oncology monitoring. J Cancer Policy 27:100284, 2021

15. Jackson M, Foster L, Wright D: Technology integration strategies for home phlebotomy programs. J Med Syst 47:28, 2023

16. Reynolds T, Parker S: Future of home diagnostics in cancer care. Curr Oncol Rep 25:123-130, 2023

17. Davis B, Fletcher J, Kumar S: Economic evaluation of home phlebotomy services: a multi-center analysis. Health Aff [Millwood] 42:387-394, 2023

18. Green P, Hall J, Stevens N: Long-term outcomes of home monitoring in oncology: a cohort study. Cancer Med 13:e6789, 2024

19. Subbiah V, Smith D, Weber L: Telehealth and remote phlebotomy in oncology during COVID-19. JCO Oncol Pract 16:617-623, 2020

20. Taylor G, Evans D, Brown C: Quality assurance protocols for decentralized phlebotomy services. Clin Lab Med 41:567-578, 2021

21. McCulloch A, MacKay WG: Home-based blood collection: a review of current practice and future prospects. Clin Chim Acta 507:144-150, 2020

22. Mendez K, Lawrence H: Microsampling technologies in cancer diagnostics: potential and limitations. Lab Med 53:130-137, 2022

23. White E, Cooper B, Hughes M: Implementation science approaches to home phlebotomy deployment. Implementation Sci 18:45, 2023

24. Morris L, Shah A: Training needs for phlebotomists in oncology home care. J Oncol Nurs 22:145-150, 2018

25. Lopez R, Wang H, Peterson K: Regulatory considerations for home-based diagnostic services. J Legal Med 43:201-215, 2022